Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeting the Prostatic Tumor Microenvironment With PLX3397, a Tumor-Associated Macrophage Inhibitor in Men With Unfavorable Risk Prostate Cancer Undergoing Radiation Therapy and Androgen Deprivation Therapy

NCT02472275 is registered in ClinicalTrials.gov with Barbara Ann Karmanos Cancer Institute as lead sponsor.

NCT NCT02472275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02472275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeting the Prostatic Tumor Microenvironment With PLX3397, a Tumor-Associated Macrophage Inhibitor in Men With Unfavorable Risk Prostate Cancer Undergoing Radiation Therapy and Androgen Deprivation Therapy
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2015
Completion date
August 5, 2019
Enrollment
8 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

stage i prostate adenocarcinoma, stage ii prostate adenocarcinoma, stage iii prostate adenocarcinoma